Research graph
References from External Validation of the ARCAD Nomogram in a Real-World Cohort with Stage 4 Colorectal Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 · External reference
Cancer statistics, 2022
2022 · External reference
Unresolved reference
External reference
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
10.1038/bjc.2011.19 · 2011 · External reference
Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients
10.1002/(sici)1097-0142(19980601)82:11<2123::aid-cncr6>3.0.co;2-w · 1998 · External reference
Gender differences in long-term survival of patients with colorectal cancer
10.1046/j.0007-1323.2001.01819.x · 2001 · External reference
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
10.1093/jnci/djw272 · 2017 · External reference
Systematic Review of Prognostic Factors Related to Overall Survival in Patients with Stage IV Colorectal Cancer and Unresectable Metastases
10.1007/s00268-010-0891-8 · 2011 · External reference
How To Build and Interpret a Nomogram for Cancer Prognosis
10.1200/jco.2007.12.9791 · 2008 · External reference
Development and external validation of a nomogram predicting overall survival after curative resection of colon cancer
2021 · External reference
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
10.1093/jnci/djx253 · 2018 · External reference
Biases in Randomized Trials
10.1097/ede.0000000000000564 · 2017 · External reference
Real-world Data for Clinical Evidence Generation in Oncology
10.1093/jnci/djx187 · 2017 · External reference
Performance Status Restriction in Phase III Cancer Clinical Trials
10.6004/jnccn.2020.7578 · 2020 · External reference
10.3390/cancers14205094
10.3390/cancers14205094 · External reference
MissForest—Non-parametric missing value imputation for mixed-type data
10.1093/bioinformatics/btr597 · 2012 · External reference
BRAF and KRAS mutations in metastatic colorectal cancer: Future perspectives for personalized therapy
10.1093/gastro/goaa022 · 2020 · External reference
Regression Modeling Strategies
2011 · External reference
External validation of prognostic models: What, why, how, when and where?
10.1093/ckj/sfaa188 · 2021 · External reference
Statistical Primer: Developing and validating a risk prediction model†
10.1093/ejcts/ezy180 · 2018 · External reference
Predicting Survival After Curative Colectomy for Cancer: Individualizing Colon Cancer Staging
10.1200/jco.2011.36.5080 · 2011 · External reference
512P External validity of the ARCAD nomogram in a real-life population of older patients with unresectable advanced colorectal cancer
10.1016/j.annonc.2020.08.622 · 2020 · External reference
Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients
10.1093/annonc/mdf034 · 2002 · External reference
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database
10.1200/jco-24-01968 · 2025 · External reference
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial
10.1016/s0140-6736(24)02848-4 · 2025 · External reference
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
10.1056/nejmoa2017699 · 2020 · External reference
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW
10.1200/jco.2024.42.16_suppl.3503 · 2024 · External reference
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
10.1056/nejmoa2501912 · 2025 · External reference
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
10.1056/nejmoa2308795 · 2023 · External reference
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC)
2026 · External reference
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
10.1056/nejmoa2212419 · 2023 · External reference
Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients
10.1002/(sici)1097-0142(19980601)82:11<2123::aid-cncr6>3.0.co;2-w · ExternalCitation · doi-reference
Systematic Review of Prognostic Factors Related to Overall Survival in Patients with Stage IV Colorectal Cancer and Unresectable Metastases
10.1007/s00268-010-0891-8 · ExternalCitation · doi-reference
512P External validity of the ARCAD nomogram in a real-life population of older patients with unresectable advanced colorectal cancer
10.1016/j.annonc.2020.08.622 · ExternalCitation · doi-reference
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial
10.1016/s0140-6736(24)02848-4 · ExternalCitation · doi-reference
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
10.1038/bjc.2011.19 · ExternalCitation · doi-reference
Gender differences in long-term survival of patients with colorectal cancer
10.1046/j.0007-1323.2001.01819.x · ExternalCitation · doi-reference
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
10.1056/nejmoa2017699 · ExternalCitation · doi-reference
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
10.1056/nejmoa2212419 · ExternalCitation · doi-reference
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
10.1056/nejmoa2308795 · ExternalCitation · doi-reference
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
10.1056/nejmoa2501912 · ExternalCitation · doi-reference
Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients
10.1093/annonc/mdf034 · ExternalCitation · doi-reference
MissForest—Non-parametric missing value imputation for mixed-type data
10.1093/bioinformatics/btr597 · ExternalCitation · doi-reference
External validation of prognostic models: What, why, how, when and where?
10.1093/ckj/sfaa188 · ExternalCitation · doi-reference
Statistical Primer: Developing and validating a risk prediction model†
10.1093/ejcts/ezy180 · ExternalCitation · doi-reference
BRAF and KRAS mutations in metastatic colorectal cancer: Future perspectives for personalized therapy
10.1093/gastro/goaa022 · ExternalCitation · doi-reference
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
10.1093/jnci/djw272 · ExternalCitation · doi-reference
Real-world Data for Clinical Evidence Generation in Oncology
10.1093/jnci/djx187 · ExternalCitation · doi-reference
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
10.1093/jnci/djx253 · ExternalCitation · doi-reference
Biases in Randomized Trials
10.1097/ede.0000000000000564 · ExternalCitation · doi-reference
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database
10.1200/jco-24-01968 · ExternalCitation · doi-reference
How To Build and Interpret a Nomogram for Cancer Prognosis
10.1200/jco.2007.12.9791 · ExternalCitation · doi-reference
Predicting Survival After Curative Colectomy for Cancer: Individualizing Colon Cancer Staging
10.1200/jco.2011.36.5080 · ExternalCitation · doi-reference
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW
10.1200/jco.2024.42.16_suppl.3503 · ExternalCitation · doi-reference
10.3390/cancers14205094
10.3390/cancers14205094 · ExternalCitation · doi-reference
Performance Status Restriction in Phase III Cancer Clinical Trials
10.6004/jnccn.2020.7578 · ExternalCitation · doi-reference
